LBPH — Longboard Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.34bn
- $2.05bn
- 37
- 22
- 91
- 48
Annual income statement for Longboard Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 14.4 | 27.8 | 44.8 | 56.8 |
| Operating Profit | -14.4 | -27.8 | -44.8 | -56.8 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -14.4 | -27.8 | -43.9 | -54.4 |
| Net Income After Taxes | -14.4 | -27.8 | -43.9 | -54.4 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -14.4 | -27.8 | -43.9 | -54.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -14.4 | -27.8 | -43.9 | -54.4 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.851 | -1.93 | -2.56 | -2.39 |
| Dividends per Share |